APPLICATION OF ANTI-IDIOTYPES TO AIDS AUTOANTIBODIES

最近的几项研究表明， 辅助性T细胞自身抗体的发展与疾病 人类免疫缺陷病毒（HIV）感染的进展。 这些研究的结果还表明， 自身抗体可能有助于获得性 免疫缺陷综合征（艾滋病）。 的主要目标 建议开发临床上有用的抗独特型（抗Id） 单克隆抗体（MoAbs），这些艾滋病相关 自身抗体 在第一阶段期间，将 产生对CD 4+特异性的细胞毒性自身抗体 从HIV感染者身上分离的淋巴细胞。 这些 自身抗体和抗Id单克隆抗体将用于开发 免疫测定法测定HIV血清自身抗体水平 感染者和对照人群。 抗- 辅助性T细胞自身抗体将与艾滋病相关 疾病参数和艾滋病毒感染的临床过程。 这些研究将持续到II期，以确定 这些诊断检测在预测艾滋病进展中的作用 在HIV感染者中。 此外，由于抗艾滋病病毒已被 用于抑制自身免疫反应，开发的抗Ids 也可能在抑制以下疾病中找到未来的治疗应用： 可能参与艾滋病发病机制的自身抗体。 总体而言，I期和II期研究的结果应导致 开发新的诊断分析和治疗产品 这可能会在未来的艾滋病毒管理中找到应用， 感染和治疗艾滋病相关疾病。

Several recent studies have demonstrated a correlation between the development of autoantibodies to helper T cells and disease progression in human immunodeficiency virus (HIV) infections. The results of these studies have also indicated that these autoantibodies may contribute to the pathogenesis of the acquired immune defeciency syndrome (AIDS). The main objective of this proposal is to develop clinically useful anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to these AIDS related autoantibodies. During the Phase I period, anti-Ids will be generated to cytotoxic autoantibodies specific for CD4+ lymphocytes isolated from individuals infected with HIV. These autoantibodies and anti-Id MoAbs will be utilized to develop immunoassays to measure serum autoantibody levels in HIV infected individuals and control populations. Detection of anti- helper T cell autoantibodies will be correlated with AIDs related disease parameters and the clinical course of HIV infections. These studies will be continued into the Phase II period to identify the role of these diagnostic assays in predicting AIDS progression in HIV infected individuals. In addition, as anti-Ids have been utilized to inhibit autoimmune responses, the developed anti-Ids may also find future therapeutic application in the suppression of autoantibodies which may be involved in AIDS pathogenesis. Overall, the results of the Phase I and II studies should lead to the development of novel diagnostic assays and therapeutic products which may find future application in the management of HIV infections and in the treatment of AIDS related disorders.